市場調査レポート

細胞療法(CT)および臍帯血市場レポート

Cellular Therapy and Cord Blood 2013 Market Report

発行 SELECTBIO, Ltd. 商品コード 261627
出版日 ページ情報 英文 172 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
細胞療法(CT)および臍帯血市場レポート Cellular Therapy and Cord Blood 2013 Market Report
出版日: 2013年02月12日 ページ情報: 英文 172 Pages
概要

当レポートでは、細胞療法(CT)および臍帯血市場について調査分析し、細胞療法における治験の動向、主な治療分野の発展、臨床段階から商業化にいたるまでの現況、地域別の分析、臍帯血市場におけるバンキングのコスト分析、臍帯血を利用したHSCTのコスト分析、米国市場と欧州市場の比較などを提供しており、概略下記の構成でお届けいたします。

第1章 細胞療法市場の情勢

  • 幹細胞市場のセグメント・産業構造
  • 細胞療法の量的動向・再生医療市場
  • 米国における再生医療・幹細胞研究活動
  • 幹細胞/再生医療部門における商用製品・サービスの売上
  • 幹細胞/再生医療分野における企業別の支出内訳
  • さまざまな分野における製品プラットf-無別の支出内訳
  • 細胞療法分野における自己移植vs.同種異系ビジネスモデル
  • 自己移植vs.同種異系の細胞療法:産業のSWOT
  • 市場スケジュール
  • 成人向け幹細胞治療の量的市場予測
  • 幹細胞研究のワークフローおよび製品開発バリューチェーン
  • さまざまな疾病クラスにおける細胞療法市場機会の量的規模
  • 細胞療法の製品パイプライン
  • 治験の量的メトリクス・詳細分析:フェーズ、細胞タイプ、対応治療分野、地域別
  • 企業および現在の市販細胞療法製品

第2章 臍帯血市場の情勢

  • HSCT情勢
  • EUにおけるHSCTの実行:対応疾病クラス別の内訳(%)
  • 北米におけるHSCTの適応:対応疾病クラス、移植者の年齢、HSC利用のタイプ、移植接種材料のクラス
  • EU vs. 米国市場におけるHSCTのコスト分析
  • HSCT関連のさまざまな処置の医療費償還コードおよび医療費償還額
  • 臍帯血の新しい・発展する情勢
  • 臍帯血バンキングの量的市場メトリクス
  • 公共バンク・登録における世界のBM、PBLおよびCBユニットの成長:国別
  • 臍帯血移植の動向:移植者の年齢、対応疾病クラス
  • 臍帯血TNC情勢・動向
  • 臍帯血バンキングのコスト内訳
  • EU・米国の臍帯血移植の詳細なコスト内訳

第3章 EUの主要市場における幹細胞の機会・資金源

第4章 EUにおける細胞療法承認のATMP規制ルート

付録?:細胞療法分野における主な市場機会

付録?:幹細胞発表ホットスポットのマッピング分析

付録:調査手法

目次

Abstract

This is the most up-to-date market report focusing on Cellular Therapy and the HSCT/Cord Blood Market Landscape, published by Select Biosciences.

In this comprehensive market report, we have focused primarily on quantitative market metrics in order to characterize the growth and evolution of the cellular therapy field--in this vein, we present primary industry data that Select Biosciences has collected as part of its continual industry tracking of this space.

We've analyzed clinical trial trends and the evolution of several therapeutics areas within cellular therapy (orthopedic, skin/wound care, cardiovascular, and CNS disorders) and present the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization. We also present the breakout of clinical trials in the bona fide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated.

Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving. Our coverage provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood. Furthermore, given our global footprint, we've been able to compare the EU and US markets side-by-side in this analysis.

Select Biosciences also presents the ATMP regulatory guidelines governing the marketing authorization of cellular therapeutics in the European Union. Details on the statute as well as implications to companies seeking to navigate this space are provided.

This Report is Written and Delivered to Customers in PowerPoint Format allowing convenient drag-and-drop for business plans, R&D presentations, investor presentations. Report purchasers receive full commercial rights to use the data and analyses presented in the report for their in-house business activities.

Extensive Market Analyses Presented in this Report:

  • Regenerative Medicine and Stem Cell Research Activity in the US
  • Sales of Commercial Products and Services in Stem Cell/Regenerative Medicine Sectors
  • Breakout of Spending by Companies in the Cellular Therapy/Regenerative Medicine Space
  • Breakout of Spending by Product Platforms in Various Spaces
  • Autologous vs. Allogeneic Business Models in the Cellular Therapy Space
  • Autologous vs. Allogeneic Cellular Therapy: Industry SWOT
  • Adult Stem Cell Therapy Quantitative Market Forecast
  • Cellular Therapy Product Pipeline
  • Clinical Trials Quantitative Metrics and Detailed Breakout by Phase, Cell Type, Therapeutic Areas Addressed, Geography
  • HSCTs Performed in the EU: Percent Breakout by Disease Classes Addressed
  • Indications for HSCTs in North America: Disease Classes Addressed, Age of Recipients, Types of HSCs Utilized, Classes of Transplant Inoculum
  • Cost Analyses of HSCTs in the EU vs. US Markets
  • Cord Blood Banking Quantitative Market Metrics
  • Growth of BM, PBL, and CB Units Worldwide in Public Banks and Registries, Segmented by Country
  • Cord Blood Transplantation Trends: Age of Recipient, Disease Classes Addressed
  • EU and US Cord Blood Transplantation Detailed Cost Breakouts
  • EU ATMP Regulation Detailed Analysis
  • Stem Cells Worldwide Publications Analysis

Table of Contents

Description of Chapters of this Report

Chapter I. Cellular Therapeutics Market Landscape

  • Stem Cell Market Segmentation and Industry Structure
  • Quantitative Trends in the Cellular Therapy and Regenerative medicine Marketplace
  • Regenerative Medicine and Stem Cell Research Activity in the US
  • Sales of Commercial Products and Services in Stem Cell/Regenerative Medicine Sectors
  • Breakout of Spending by companies in the Cellular Therapy/Regenerative Medicine Space
  • Breakout of Spending by Product Platforms in Various Spaces
  • Autologous vs. Allogeneic Business Models in the cellular Therapy Space
  • Autologous vs. Allogeneic Cellular Therapy: Industry SWOT
  • Market Timeline
  • Adult Stem Cell Therapy Quantitative Market Forecast
  • Stem Cell Research Workflow and Product Development Value Chain
  • Quantitative Scale of Cellular Therapy Market Opportunities in Various Disease Classes
  • Cellular Therapy Product Pipeline
  • Clinical Trials Quantitative Metrics and Detailed Breakout by Phase, Cell Type, Therapeutic Areas Addressed, Geography
  • Companies and Marketed Cellular therapy Products Currently

Chapter II. Cord Blood Market Landscape

  • The HSCT Landscape
  • HSCTs Performed in the EU: Percent Breakout by Disease Classed Addressed
  • Indications for HSCTs in North America: Disease Classes Addressed, Age of Recipients, Types of HSCs Utilized, Classes of Transplant Inoculum
  • Cost Analyses of HSCTs in the EU vs. US Markets
  • Reimbursement Codes and Reimbursed Amounts for Various Procedures Associated with HSCTs
  • The Emerging and Evolving Cord Blood Landscape
  • Cord Blood Banking Quantitative Market Metrics Growth of BM, PBL, and CB Units Worldwide in Public Banks and Registries, Segmented by Country
  • Cord Blood Transplantation Trends: Age of Recipient, Disease Classes Addressed
  • Cord Blood TNCs Landscape and Trends
  • Cord Blood Banking Cost Breakouts
  • EU and US Cord Blood Transplantation Detailed Cost Breakouts

Chapter III. Stem Cell Opportunities and Funding Sources in Some of the Top Markets Across the European Union

Chapter IV. ATMP Regulatory Routes for Approval of Cellular Therapies in the European Union

Appendix I. Selected market Opportunities in the Cellular therapeutics Space

Appendix II. Stem Cell Publications Hotspot Mapping Analysis

Appendix III. Research Methodology

Back to Top